MedTrace Logo

Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients

NCT00364052 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2006-08-17

No results posted yet for this study

Summary

Null Hypothesis:

There is no significant difference in the incidence of CMV infection when using oral valganciclovir or ganciclovir as prophylactic anti-viral therapy.

Alternate Hypothesis:

There exists a significant difference in the incidence of CMV infection when oral valganciclovir is used for CMV prophylaxis rather than oral ganciclovir. A formal hypothesis to be tested should be defined.

Conditions

  • Liver Transplantation

Interventions

DRUG

oral Valganciclovir vs oral Ganciclovir

Sponsors & Collaborators

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Ali J Olyaei, PharmD · Oregon Health and Science University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Completion
2007-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00364052 on ClinicalTrials.gov